Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Clifford

Showing results (241-250 of 325) with videos related to

Pageof 33
Sort By:
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2013
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorderRonald J Ellis, Scott Letendre, Florin Vaida, et al.
Journal of Neurovirology|June 13, 2015
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV diseaseAlbert M Anderson, Christine Fennema-Notestine, Anya Umlauf, et al.
AIDS (London, England)|March 15, 2019
Effects of comorbidity burden and age on brain integrity in HIVRowan Saloner, Robert K Heaton, Laura M Campbell, et al.
The Clinical Neuropsychologist|June 20, 2012
Defining neurocognitive impairment in HIV: deficit scores versus clinical ratingsK Blackstone, D J Moore, D R Franklin, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2012
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationDavid Croteau, Steven S Rossi, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patientsLucette A Cysique, Bruce J Brew, Mark Halman, et al.
The Lancet. HIV|June 19, 2019
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort studyAlessandro Livelli, Florin Vaida, Ronald J Ellis, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Therapeutic amprenavir concentrations in cerebrospinal fluidDavid Croteau, Scott Letendre, Brookie M Best, et al.
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Pageof 33

Showing results (241-250 of 325) with videos related to

Sort By:
Pageof 33
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2013
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorderRonald J Ellis, Scott Letendre, Florin Vaida, et al.
Journal of Neurovirology|June 13, 2015
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV diseaseAlbert M Anderson, Christine Fennema-Notestine, Anya Umlauf, et al.
AIDS (London, England)|March 15, 2019
Effects of comorbidity burden and age on brain integrity in HIVRowan Saloner, Robert K Heaton, Laura M Campbell, et al.
The Clinical Neuropsychologist|June 20, 2012
Defining neurocognitive impairment in HIV: deficit scores versus clinical ratingsK Blackstone, D J Moore, D R Franklin, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2012
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationDavid Croteau, Steven S Rossi, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patientsLucette A Cysique, Bruce J Brew, Mark Halman, et al.
The Lancet. HIV|June 19, 2019
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort studyAlessandro Livelli, Florin Vaida, Ronald J Ellis, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Therapeutic amprenavir concentrations in cerebrospinal fluidDavid Croteau, Scott Letendre, Brookie M Best, et al.
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Pageof 33